Insider Selling: SiBone (NASDAQ:SIBN) Director Sells $369,200.00 in Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $18.46, for a total transaction of $369,200.00. Following the sale, the director owned 16,057 shares in the company, valued at approximately $296,412.22. This trade represents a 55.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

SiBone Stock Up 2.6%

Shares of NASDAQ:SIBN opened at $18.61 on Friday. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The firm has a fifty day moving average of $16.62 and a 200 day moving average of $15.17. The firm has a market capitalization of $825.35 million, a PE ratio of -54.74 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 8.34 and a current ratio of 9.15.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%.The business had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. As a group, research analysts anticipate that SiBone will post -0.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SIBN has been the topic of a number of recent research reports. TD Cowen increased their price target on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday. Truist Financial reaffirmed a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday. Weiss Ratings lowered shares of SiBone from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Wall Street Zen cut shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, UBS Group boosted their price target on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.29.

Institutional Investors Weigh In On SiBone

Several institutional investors and hedge funds have recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd purchased a new position in shares of SiBone during the fourth quarter valued at approximately $29,000. Versant Capital Management Inc lifted its stake in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after acquiring an additional 887 shares during the period. Royal Bank of Canada boosted its holdings in SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after acquiring an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in SiBone by 64,700.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in SiBone during the 4th quarter valued at $53,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.